Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma

Figure 1 A flow diagram of 187 obstructive jaundice patients who were consecutively enrolled in this study.

Figure 2 Serum levels of carbohydrate antigen 19-9 and matrix metalloproteinase-7 in cholangiocarcinoma and control (benign biliary tract disease) patients. A: Box plots comparing levels of carbohydrate antigen 19-9 (CA19-9); B: Matrix metalloproteinase-7 (MMP7) between cholangiocarcinoma and control patients are illustrated; C: Box plots comparing levels of CA19-9; D: MMP7 between early and advanced stages of cholangiocarcinoma and controls are illustrated. Levels of MMP7 are presented as ng/mL, while CA19-9 is presented with the log data to accommodate the wide range. (^bMann-Whitney U, P < 0.001 vs control; ^dStudent's t-test, P < 0.001 vs control; ^eKruskal Wallis test, P < 0.001 vs control; ^fANOVA, P < 0.001 vs control).

Figure 3 Receiver operating characteristic curve analyses of carbohydrate antigen 19-9 and matrix metalloproteinase-7 for the diagnosis of cholangiocarcinoma. The diagnostic accuracy of each biomarker, in terms of its sensitivity and specificity, are presented by receiver operating characteristic curve analysis. MMP7: Matrix metalloproteinase-7; CA19-9: Carbohydrate antigen 19-9.